Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

This trial is studying whether adding a CDK4/6 inhibitor (a type of targeted drug that slows cancer cell growth) to standard hormone-blocking therapy before surgery helps shrink hormone-receptor-positive, HER2-negative breast cancer more effectively. **You may be eligible if...** - You are a woman aged 18–75 with newly diagnosed breast cancer - Your cancer is hormone receptor-positive and HER2-negative (confirmed by pathology) - Your primary tumor is larger than 2 cm - Your cancer is classified as stage II or III (has not spread to distant organs) - You have not yet started treatment **You may NOT be eligible if...** - You have HER2-positive or triple-negative breast cancer - Your cancer has spread to distant parts of the body - You are older than 75 or under 18 - You have significant other health conditions Talk to your doctor to see if this trial is right for you.